Last week Pixels & Pills’ editor Briana Campbell had the pleasure of sitting down for a Skype chat (so the quality is a little lower than our normal, professional videos) with Dr. Darshan Kulkarni (@FDALawyers) of the Kulkarni Law Firm in Philadelphia. And while the questions answered in the conversation don’t constitute legal advice and [...]
Tags:#hcsm·@FDALawyers·Darshan Kulkarni·FDA·FDA Guidance·information·innovation·legal·Legal Issues·marketing·resources·social media·social media guidance·social media guidelines·Trends·Video
by DJ Edgerton (@wiltonbound)
The question seems almost nonsensical at first – your Twitter followers may be really outstanding people, but they’re not organic chemists or researchers. And your Facebook fans, while devoted, probably do not, generally speaking, know how to move a new drug through the FDA approval process.
Just the same, it’s a mistake to [...]
Tags:Compliance·data·digital strategy·Digital Tools·Education·engagement·epatient·FDA·information·innovation·Legal Issues·marketing·Pharma·Pharmaceutical industry·R&D·research and development·social media·Social network·strategy·technology·Trends·user needs
by Krissy Goelz (@krisgoelz)
Recently, we were asked what we thought about how Google+ could affect healthcare, by someone who had read an Xconomy post on the same question.
So, does this newest, mega-hyped social network have the potential to really transform the industry? As you’ve seen with our many point/counterpoint articles, we like to [...]
Tags:Digital Tools·Education·engagement·Facebook·Google·Google Plus·Health care·healthcare·innovation·Legal Issues·social media·Social network·Trends·user needs
by Russ Ward (@russcward)
Browse through the business press, and you won’t have to search long before you find articles about pharma, patents and a whole lot of drama. From a patient perspective, what’s the big deal?
The issue: Within the next few years, multiple pharma companies are set to lose their exclusive production rights to some [...]
Tags:drug patents·Legal Issues·marketing·patent·patents·patient·Patients·Pharma·Pharmaceutical industry·Trends
The Defining Moments series looks back at the biggest events of 2010 to see what we can learn from them here at P&P, to work better in our calling, in 2011 and beyond.
Where were you on Wednesday, October 13, 2010?
I’m willing to bet that, at least at one point [...]
Tags:chilean miners·defining moments·digital strategy·Digital Tools·Education·FDA·Legal Issues·marketing·Pharmaceutical industry·strategy·technology
Here at Pixels & Pills, we’re always trying to push the conversation about health and pharma in the digital space harder and farther along. Which is why we were intrigued when Shwen Gee let us know about The Social Health Un-Conference (SXSH), taking place September 19th, right before ePatient Connections.
Aside from the impressive speaker list [...]
Tags:communication·Communities·community·conference·Conferences·Education·engagement·events·Health·Health care·information·innovation·Legal Issues·Patients·Pharma·Pharmaceutical industry·social media·Social network·Thought Leaders·Trends·user needs
by Briana Campbell (@MsMatchGirl)
The talk, for a long while now, has been about Facebook’s change of guidelines, no longer allowing pharmaceutical companies to turn off comments on their Facebook walls. Yesterday, D-Day arrived.
Over on Dose of Digital, Jonathan Richman, was keeping a “deathwatch” vigil over pages that were apt to be removed. On Friday, the [...]
Tags:communication·Communities·community·digital strategy·Digital Tools·engagement·Facebook·FDA·information·innovation·Legal Issues·Pharma·Pharmaceutical industry·social media·Social network·technology
by Briana Campbell (@MsMatchGirl)
There has been a lot of talk, over the past few months, over Facebook’s changing commenting policies and the pharma industry. Our friend Jonathan Richman clears things up nicely on Dose of Digital, so we won’t bother going into too much detail here. Basically, though, Facebook has changed its policy regarding comments [...]
Tags:#hcsm·communication·Facebook·FDA·innovation·Legal Issues·marketing·Pharma·Pharmaceutical industry·social media·Social network·tools
by Jon Fisher (@jmfisher)
Summer days used to mean scraped knees from wiping out on a bicycle or not heeding a lifeguard’s warning about no running around the swimming pool. These days? My fear of getting scraped is no longer from a reckless streak or summer sports; Like others sharing personal and health information online, I’ve [...]
Tags:communication·Communities·community·Legal Issues·patient·Patients·privacy·social media·Trends
by Krissy Goelz (@krisgoelz)
We’re not the first ones to tell you that Facebook is changing its commenting policy for pharma pages. Lots of our compatriots have done that in recent days. For a particularly great summary, check out Jonathan Richman’s Dose of Digital: he’s got the full story.
No, we’re not [...]
Tags:communication·Communities·community·Digital Tools·FDA·Legal Issues·social media·Social network·technology·Trends
